Drug Profile
R 125224
Alternative Names: CS 9507; R125224Latest Information Update: 04 Apr 2007
Price :
$50
*
At a glance
- Originator Daiichi Sankyo Inc
- Class Antirheumatics; Monoclonal antibodies
- Mechanism of Action Apoptosis stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Autoimmune disorders; Rheumatoid arthritis
Most Recent Events
- 03 Apr 2006 Daiichi Pharmaceutical has merged with Sankyo to form Daiichi Sankyo Inc
- 24 Jun 2004 Preclinical trials in Autoimmune disorders in Japan (unspecified route)
- 24 Jun 2004 Data presented at the Annual European Congress of Rheumatology (EULAR-2004) have been added to the Rheumatic Disease and Immunological disorders pharmacodynamics sections ,,,